Rentschler names Benedikt von Braunmuehl as CEO; Catalent grabs David McErlane from Lonza as biologics lead

Benedikt von Braunmuehl has been revealed as Rentschler Biopharma’s new CEO. Meanwhile, Catalent also announced that David McErlane is the CDMO’s new group president of its biologic segment.

Von Braunmuehl, the former CEO of HMNC Brain Health, replaced Frank Mathias, who shifted to Oxford Biomedica in February after seven years at Rentschler. Tuesday marks von Braunmuehl’s first day on the job.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

New approach to treat post-COVID symptoms

In a world still grappling with the aftermath of the COVID-19 pandemic, a team of international researchers has proposed a novel approach to treating the

September 4, 2024

Gender-affirming surgeries tripled in the U.S. between 2016-2019, study finds

The number of gender-affirming surgeries taking place in the U.S. nearly tripled between 2016 and 2019, according to new national estimates from a cohort study

August 23, 2023

MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study – Biotech Investments

EQS-News: MorphoSys AG / Key word(s): Conference MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study 11.12.2023 / 01:31 CET/CEST The

December 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.